BiotechTube

Solriamfetol 150 MG + Placebo

Phase 3Recruiting
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms

Conditions

Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms

Trial Timeline

Feb 23, 2026 → Dec 1, 2028

NCT ID
NCT07484217

About Solriamfetol 150 MG + Placebo

Solriamfetol 150 MG + Placebo is a phase 3 stage product being developed by Axsome Therapeutics for Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07484217. Target conditions include Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT07484217Phase 3Recruiting

Competing Products

20 competing products in Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms

See all competitors
ProductCompanyStageHype Score
Duloxetine HydrochlorideEli LillyPre-clinical
23
LY2216684Eli LillyPhase 1
33
LY2216684Eli LillyPhase 1
33
DuloxetineEli LillyPhase 3
77
LY2216684 + DigoxinEli LillyPhase 1
33
Duloxetine + ParoxetineEli LillyPhase 3
77
Duloxetine + placeboEli LillyPhase 3
77
LY2216684 + Placebo + EscitalopramEli LillyPhase 2
52
FK949EAstellas PharmaPhase 1
33
quetiapine extended release (XR) + PlaceboAstellas PharmaPhase 2
52
FK949EAstellas PharmaPhase 1
33
FK949EAstellas PharmaPhase 1
33
FK949EAstellas PharmaPhase 1
33
Mirtazapine TabletsSun PharmaceuticalApproved
85
ONO-2333Ms Experimental 2 + Placebo + ONO-2333Ms Experimental 1Ono PharmaceuticalPhase 2
52
ONO-1110 + PlaceboOno PharmaceuticalPhase 2
52
Pramipexole ER + EscitalopramCiplaPhase 2
52
LY2216684 + SertralineEli LillyPhase 1
33
LY2216684 + Placebo + LorazepamEli LillyPhase 1
33
LY2216684 + SSRIEli LillyPhase 3
77

Other Products from Axsome Therapeutics

Solriamfetol + PlaceboApproved
82
Solriamfetol 75 MGApproved
82
AXS-05 + BupropionApproved
82
Solriamfetol Oral Tablet + PlaceboApproved
82
AXS-05 (dextromethorphan and bupropion) oral tabletsPhase 3
74